Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study

BACKGROUND: Lenvatinib (LEN) combined with anti-PD-1 antibodies (PD-1) exerted promising effects on unresectable hepatocellular carcinoma (uHCC). We assessed the safety and clinical efficacy of triple therapy [LEN+PD-1+transcatheter arterial chemoembolization (TACE)] in uHCC. METHODS: uHCC patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jia-Yi, Yin, Zhen-Yu, Bai, Yan-Nan, Chen, Yu-Feng, Zhou, Song-Qiang, Wang, Shuang-Jia, Zhou, Jian-Yin, Li, Yi-Nan, Qiu, Fu-Nan, Li, Bin, Yan, Mao-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502053/
https://www.ncbi.nlm.nih.gov/pubmed/34676181
http://dx.doi.org/10.2147/JHC.S332420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502053/
https://www.ncbi.nlm.nih.gov/pubmed/34676181
http://dx.doi.org/10.2147/JHC.S332420

Ejemplares similares